Strong Profit Surge as MeCure Navigates Nigeria’s Evolving Economy

In the first quarter of 2026, MeCure Industries PLC recorded a strong financial performance, successfully navigating a still challenging but gradually stabilizing macroeconomic environment in Nigeria and across the globe.

This was disclosed in a statement issued by the company’s media office and made available to journalists.

The Company reported revenue of ₦20.15 billion, representing a 52 percent year-on-year increase. Profit Before Tax (PBT) stood at ₦1.92 billion, marking a 136 percent year-on-year growth, while Earnings Per Share (EPS) rose to ₦0.34, reflecting a 143 percent year-on-year increase.

Nigeria’s economy in early 2026 continues to adjust to the impact of structural reforms implemented over the past year, including foreign exchange liberalization and tight monetary policies targeted at reducing inflation. Although inflation remains high, it has begun to moderate gradually, while exchange rate volatility, though still present, has become relatively more predictable. These trends, combined with improving global supply chain conditions and easing energy price pressures, have contributed to a cautiously improving operating environment for manufacturers.
Within this environment, MeCure’s Q1 performance highlights the strength of its strategic positioning. The Company continues to benefit from sustained investments in local manufacturing capacity, which reduces exposure to foreign exchange risks and enhances cost efficiency. In addition, improved procurement strategies and diversified supply chains have helped manage input cost volatility and ensure consistent product availability across key markets.
Despite persistent cost pressures, particularly from high borrowing costs in a high-interest-rate environment and inflation-driven increases in operating expenses, the Company maintained strong profitability growth. This performance was driven by disciplined cost management, an improved product mix, and a sustained focus on high-margin therapeutic segments.

The significant growth in PBT and EPS reflects improved operational efficiency and the Company’s ability to convert revenue growth into increased shareholder value.

Furthermore, supportive government policies, including incentives for local pharmaceutical manufacturing, have helped offset the impact of imported input costs and reinforced the Company’s long-term strategy of expanding local production.

Looking ahead, MeCure remains committed to sustaining its growth trajectory through capacity expansion, innovation, and deeper market penetration. While macroeconomic uncertainties persist both locally and globally, the Company is well positioned to take advantage of emerging opportunities in Nigeria’s healthcare sector and continue delivering value to stakeholders.